Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5761317 | 0.89 | POLB (0.44) | LMNAALDH1A1KMT2AL3MBTL1CYP2C19 | |
| SCHEMBL5761722 | 0.88 | GAA (0.56) | LMNAALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL5361897 | 0.85 | KMT2A (0.43) | LMNAALDH1A1KMT2AL3MBTL1CYP3A4 | |
| SCHEMBL5761990 | 0.83 | KMT2A (0.50) | LMNAALDH1A1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL11703033 | 0.82 | ALDH1A1 (0.56) | LMNAALDH1A1KMT2AL3MBTL1CYP3A4 | |
| SCHEMBL5760942 | 0.82 | KMT2A (0.45) | LMNAALDH1A1KMT2AL3MBTL1GAA | |
| SCHEMBL14578750 | 0.81 | LMNA (0.61) | LMNAALDH1A1KMT2ACYP3A4CYP2C9 | |
| SCHEMBL3391356 | 0.81 | GAA (0.52) | LMNAALDH1A1KMT2ACYP3A4CYP2C19 | |
| SCHEMBL5760908 | 0.79 | GAA (0.43) | LMNAALDH1A1KMT2AMEN1GAA | |
| SCHEMBL5761411 | 0.79 | ALDH1A1 (0.38) | LMNAALDH1A1KMT2AL3MBTL1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556371-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PRODRUGS OF PROTON PUMP INHIBITOR | WINSTON PHARMACEUTICALS LLC (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20050182101-A1 | Prodrugs of proton pump inhibitors | GARST MICHAEL (US) | 2005-08-18 | — | — | US | disclosed |
| EP-1556371-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PRODRUGS OF PROTON PUMP INHIBITOR | Winston Pharmaceuticals LLC (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20050143423-A1 | Prodrugs of proton pump inhibitors background of the invention | GARST MICHAEL (US) | 2005-06-30 | — | — | US | disclosed |
| US-6897227-B2 | Prodrugs of proton pump inhibitors | Winston Pharmaceuticals, Inc. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040102484-A1 | Prodrugs of proton pump inhibitors | ALEVIUM PHARMACEUTICALS, INC. | 2004-05-27 | — | — | US | disclosed |
| WO-2004009583-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PRODRUGS OF PROTON PUMP INHIBITOR | GARST MICHAEL E (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102484-A1 | Prodrugs of proton pump inhibitors | ABCB11, SLC10A2, SI | LMNA 4395/4885ALDH1A1 397/4885KMT2A 2483/4885 |
| US-20050143423-A1 | Prodrugs of proton pump inhibitors background of the invention | ABCB11, SLC10A2, SI | LMNA 4347/4885ALDH1A1 405/4885KMT2A 2592/4885 |
| US-20050182101-A1 | Prodrugs of proton pump inhibitors | ABCB11, SLC10A2, SI | LMNA 4415/4885ALDH1A1 494/4885KMT2A 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.